MiniMed Group, Inc. (Ticker: MMED US) is an American company specializing in diabetes care technology, including automated insulin pumps, continuous glucose monitors, and smart insulin pens. MiniMed plans to list on the NASDAQ on March 5, 2026, offering 28 million shares at a price range of $25.00 to $28.00 per share. The IPO is expected to raise up to $784 million, giving the company an estimated market capitalization of up to $7.86 billion. The company is going public as a spin-off from its parent company, Medtronic.

Post-IPO, Medtronic will reportedly retain a 90% stake before planning a complete split-off to shareholders 180 days later. According to sources, MiniMed plans to use the IPO proceeds to repay intercompany debt and purchase assets, while retaining $350 million in cash. The company reportedly operates in approximately 80 countries with a workforce of 8,000 employees, serving over 640,000 users. For the trailing twelve months ending in October 2024, the business reportedly generated $2.89 billion in revenue.